All News
English for the Biologically-Challenged (8.4.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.
Read Article
Rheumatology Journals Rife With Faulty Conflict-of-Interest
More often than not, conflict-of-interest disclosures in three major rheumatology journals didn't match records in the U.S. government's Open Payments database, researchers found.
https://t.co/LKyEURZrQY https://t.co/EQLSWXB3o2
Links:
Dr. John Cush RheumNow ( View Tweet)
Mark your calendars! The highly anticipated Association of Women in Rheumatology 2023 conference is just a few weeks away! Don't miss this incredible opportunity to join in virtually for FREE! Register now and secure your spot https://t.co/qqq4c1p6De
Australian Rheumatology Association AusRheum ( View Tweet)
Multi-media, sponsor-generated clinical trial posters presented at major rheumatology meetings are now available in RheumNow’s newest offering: the Poster Hall.
https://t.co/4WRpwh8iRa https://t.co/ZGKDqfjb7Y
Links:
Dr. John Cush RheumNow ( View Tweet)
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
https://t.co/gGsBr1s0RE https://t.co/Ku6tdzit84
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR.
https://t.co/XQL7bfkkho https://t.co/HJ2aSIG0rn
Links:
Dr. John Cush RheumNow ( View Tweet)
Spinal CT study of 40 ankylosing spondylitis pts shows the most common site and region of intervertebral fusion were the posterior vertebrae of the middle thoracic region >50% halffused posterior vertebrae Th4–Th5 to Th7–Th8, followed by Cx, last lumbar https://t.co/HzJmpROJmr https://t.co/9qUwlGyBQz
Links:
Dr. John Cush RheumNow ( View Tweet)
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial lung disease
- anti-Ro52 antibody
- age > 57 years
(based on study of 126 MDA-5+ DM pts)
https://t.co/JLGIgALUip https://t.co/boTTzrixk9
Links:
Dr. John Cush RheumNow ( View Tweet)
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given for either hemolytic anemia or ITP (11 pts), nephritis & CNS SLE (5 pts ea). BEL mostlyfor arthritis (8 pts) https://t.co/cgC837Na81 https://t.co/bndKVqNsSE
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/F0aQR7ZDeU https://t.co/ugXkDmOVML
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/uJjr7rTIJe https://t.co/ptTvwWJlvO
Links:
Dr. John Cush RheumNow ( View Tweet)
Multi-media, sponsor-generated clinical trial posters presented at major rheumatology meetings are now available in RheumNow’s newest offering: the Poster Hall.
https://t.co/YQW2wN9X25 https://t.co/BS9jZRLUo4
Links:
Dr. John Cush RheumNow ( View Tweet)
Composite Measures to Inform Treatment Choices in Bio-naïve Patients with PsA
What is an option for treating and managing bio-naïve patients with PsA?
Dr. Mease and Dr. Khattri discuss.
Therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/xha5gyHqor https://t.co/mINKK0ybVD
Links:
Dr. John Cush RheumNow ( View Tweet)
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
https://t.co/4k6DNJie4n https://t.co/BbPlEFAGH3
Links:
Dr. John Cush RheumNow ( View Tweet)
Paradoxical Rxns (PR) & biologics in TReasure database: 2867 RA & 5316 SpA pts; 5-yr FUV found 136 pts (1.7%) developed the PRs; 60% w/ 1st biologic, after median 12 mos, 93% psoriais (pustular 60%, palmoplantar 31%), many better w/ another TNFi https://t.co/5tybXZZVKW https://t.co/1nQaXQOEDD
Links:
Dr. John Cush RheumNow ( View Tweet)
HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7
Links:
Dr. John Cush RheumNow ( View Tweet)
Bifunctional B-cell Targeted Therapy in IgG4-related Disease
A novel B-cell depletion trial, using obexelimab has shown efficacy and safety in patients with active IgG4-related disease.
https://t.co/JTfOrOLrrY https://t.co/ANY2YL25jT
Links:
Dr. John Cush RheumNow ( View Tweet)
Johns Hopkins & Univ Pittsburgh Scleroderma compared autoantibodies in 676 SSc pts w/ hx of cancer to 687 SSc controls without CA. Anti-POLR3 & anti-Ro52 assoc w. significantly increased cancer risk; Centromere & U1RNP had a decreased cancer risk https://t.co/z6HfRR7PWs https://t.co/zISZlgHGjd
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheums: Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/uY9Mwyrsn3
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR.
https://t.co/sJcq9lMP1l https://t.co/zvmPs3SdCw
Links:
Dr. John Cush RheumNow ( View Tweet)
